疱疹病毒对阿糖胞苷的敏感性：敏感性试验程序的标准化及2型单纯疱疹病毒株的相对抗性
Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains.
作者信息
Fiala M, Chow A, Guze L B
出版信息
Antimicrob Agents Chemother. 1972 Apr;1(4):354-7. doi: 10.1128/AAC.1.4.354.
Abstract
Susceptibility testing of herpes simplex type 1 (HSV-1) and type 2 (HSV-2) viruses to cytosine arabinoside (Ara-C) has been standardized under conditions of optimal reproducibility, susceptibility, and simplicity. Standard conditions were defined as virus inoculum of 10(1.5) to 10(2.5) TCID(50), WI-38 strain of lung fibroblasts, 2-day incubation, and observation of virus cytopathic effect after staining by the May-Greenwald-Giemsa method. The variability of minimum inhibitory concentration (MIC) of cytopathic effect was fourfold within each test and sixfold in successive assays. MIC values of all seven tested HSV-1 strains were in the range of 0.25 to 0.75 mug per ml, whereas four of nine HSV-2 strains had MIC values of 0.9 mug per ml and greater. A similar method can be used for assay of virus inhibitory titers of body fluids.
摘要
对单纯疱疹病毒1型（HSV - 1）和2型（HSV - 2）进行阿糖胞苷（Ara - C）敏感性试验，已在最佳重复性、敏感性和简易性条件下实现标准化。标准条件定义为：病毒接种量为10(1.5)至10(2.5)半数组织培养感染剂量（TCID(50)），WI - 38肺成纤维细胞株，培养2天，并采用美-格-姬氏染色法染色后观察病毒细胞病变效应。每次试验中细胞病变效应的最低抑菌浓度（MIC）变化为4倍，连续试验中为6倍。所有7株受试HSV - 1菌株的MIC值在每毫升0.25至0.75微克范围内，而9株HSV - 2菌株中有4株的MIC值为每毫升0.9微克及更高。类似方法可用于检测体液的病毒抑制效价。
相似文献
1
Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains.
Antimicrob Agents Chemother. 1972 Apr;1(4):354-7. doi: 10.1128/AAC.1.4.354.
2
Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination.
J Clin Invest. 1978 Dec;62(6):1142-53. doi: 10.1172/JCI109233.
3
Variables influencing the in vitro susceptibilities of herpes simplex viruses to antiviral drugs.
Antimicrob Agents Chemother. 1974 Jul;6(1):34-8. doi: 10.1128/AAC.6.1.34.
4
Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iododeoxyuridine, cytosine arabinoside, and adenine arabinoside.
Antimicrob Agents Chemother. 1975 Dec;8(6):643-50. doi: 10.1128/AAC.8.6.643.
5
Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine.
J Infect Dis. 1976 Oct;134(4):400-4. doi: 10.1093/infdis/134.4.400.
6
Herpes simplex virus latency in cultured human cells following treatment with cytosine arabinoside.
J Gen Virol. 1972 Feb;14(2):189-97. doi: 10.1099/0022-1317-14-2-189.
7
A rapid antiviral drug test by enzyme-linked immunoassay.
Diagn Immunol. 1983;1(4):284-7.
8
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.
Antimicrob Agents Chemother. 1980 Apr;17(4):558-66. doi: 10.1128/AAC.17.4.558.
9
Cytopathogenicity, drug susceptibility, and thymidine kinase activity of a retinovirulent herpes simplex virus type 2.
J Med Virol. 1990 Aug;31(4):301-5. doi: 10.1002/jmv.1890310411.
10
Simplified test for detecting the resistance of herpes simplex virus to acyclovir.
J Med Virol. 1990 Jul;31(3):209-14. doi: 10.1002/jmv.1890310307.
引用本文的文献
1
Inhibition of herpes simplex virus replication by phosphonoacetic acid.
Antimicrob Agents Chemother. 1974 Sep;6(3):360-5. doi: 10.1128/AAC.6.3.360.
2
Variables influencing the in vitro susceptibilities of herpes simplex viruses to antiviral drugs.
Antimicrob Agents Chemother. 1974 Jul;6(1):34-8. doi: 10.1128/AAC.6.1.34.
3
Inactivation of herpes simplex virus by thiosemicarbazones and certain cations.
Antimicrob Agents Chemother. 1974 Apr;5(4):398-402. doi: 10.1128/AAC.5.4.398.
4
Assessment of cytosine arabinoside as an antiviral agent in humans.
Antimicrob Agents Chemother. 1974 Nov;6(5):598-602. doi: 10.1128/AAC.6.5.598.
5
Cytosine arabinoside therapy for herpes simplex encephalitis--clinical experience with six patients.
Antimicrob Agents Chemother. 1973 Mar;3(3):412-7. doi: 10.1128/AAC.3.3.412.
6
The latent herpes simplex virus.
Bacteriol Rev. 1974 Dec;38(4):337-55. doi: 10.1128/br.38.4.337-355.1974.
7
Inactivation of Herpesvirus hominis types 1 and 2 by silver nitrate in vitro and in vivo.
Antimicrob Agents Chemother. 1973 Sep;4(3):259-62. doi: 10.1128/AAC.4.3.259.
8
Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine.
Antimicrob Agents Chemother. 1975 May;7(5):587-95. doi: 10.1128/AAC.7.5.587.
9
A combined chemical-physical treatment for herpes simplex lesions in guinea pigs.
Arch Dermatol Res. 1979 May 29;265(1):71-7. doi: 10.1007/BF00412703.
10
Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice.
Antimicrob Agents Chemother. 1976 Mar;9(3):458-64. doi: 10.1128/AAC.9.3.458.
本文引用的文献
1
Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2'-Deoxyuridine and 9-beta-d-Arabinofuranosyladenine.
Infect Immun. 1970 Dec;2(6):815-20. doi: 10.1128/iai.2.6.815-820.1970.
2
INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES.
J Immunol. 1964 Oct;93:643-8.
3
CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS.
Arch Ophthalmol. 1964 Oct;72:505-12. doi: 10.1001/archopht.1964.00970020505014.
4
CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE.
Proc Soc Exp Biol Med. 1964 Jan;115:69-77. doi: 10.3181/00379727-115-28834.
5
Influence of host cell on biologic markers of types 1 and 2. Herpesvirus hominis.
J Infect Dis. 1971 Feb;123(2):169-77. doi: 10.1093/infdis/123.2.169.
6
In vitro determinations of viral susceptibility to drugs for possible clinical use.
Antimicrob Agents Chemother (Bethesda). 1970;10:380-4.
7
Severe generalized primary herpes treated with cytarabine.
Br Med J. 1970 Apr 18;2(5702):154-5. doi: 10.1136/bmj.2.5702.154.
8
Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia.
Blood. 1969 Nov;34(5):706-11.
9
Investigation of plaque formation in chick embryo cells as a biological marker for distinguishing herpes virus type 2 from type 1.
J Gen Virol. 1971 Jan;10(1):1-9. doi: 10.1099/0022-1317-10-1-1.
10
Cytosine arabinoside therapy for herpesvirus infections.
Antimicrob Agents Chemother (Bethesda). 1970;10:214-7.
Zotero 插件